Episurf Medical (EPIS-B)

[holmes]

Det er en mellomstasjon før bta og overtegning blir til nye aksjer. Egentlig bare en måte å sørge for at aksjene hele tiden er likvide så du ikke låser penger inne uten å kunne selge.

[Savepig]

NASDAQ OMX GlobeNewswire Post # 242562

rights issue was subscribed for by shareholders to approximately 91.5 per cent, which means that Episurf Medical receives approximately SEK 109.5 million before issue related costs.

Vil si det er sånn midt på treet. En kunne ikke forvente overtegning når en så at tegningsrettene ble gratis.

http://episurf.com/app/files/Episurf_Q4_2016_ENG.pdf

Operating loss i Q4 var –18,285,401

Så Episurf har ca et år på seg til å bevise at dette kan bli en business?

OUTCOME OF EPISURF MEDICAL’S RIGHTS ISSUE
This information was published, 2017-03-16 07:30 CET (GLOBE NEWSWIRE) –

The subscription period for Episurf Medical’s new issue of A and B shares with preferential right for the company’s shareholders ended on 13 March 2017 and the final outcome shows that the rights issue was subscribed for by shareholders to approximately 91.5 per cent, which means that Episurf Medical receives approximately SEK 109.5 million before issue related costs.

In accordance with the resolution of the shareholders’ meeting on 20 February 2017, which approved the board of directors’ resolution on a new issue of A and B shares with preferential rights for the Company’s shareholders, Episurf Medical AB (publ) (“Episurf Medical” or the “Company”) has carried out the new issue (the “Rights Issue”). The subscription price for the new shares of series A and B was SEK 7.50 per share and the subscription period took place from and including 27 February 2017 until and including 13 March 2017.

The Rights Issue was subscribed for to 91.5 per cent. The summation shows that 13,477,883 shares (of which 2,983,597 A shares and 10,494,286 B shares), corresponding to 84.5 per cent of the offered shares, were subscribed for by subscription rights. 1,121,808 shares, corresponding to 7.0 per cent of the offered shares, were subscribed for without subscription rights. This means that 14,599,691 shares (of which 2,985,597 A shares and 11,614,094 B shares) will be issued. Hence, the Company will raise approximately SEK 109.5 million before issue related costs, which means that the guarantee commitments do not have to be used.

“The rights issue represents a significant capital contribution for Episurf and it enables us to execute upon our growth plan. We are seeing a great interest in our technology and our products and an increasing number of orthopaedic surgeons are turning to our solution for treatment of patients with cartilage and bone lesions of the knee joint. Our clinical portfolio is growing steadily and to date, approximately 180 patients have been treated with our implants. In step with this we are strengthening our opportunities to establish Episealer and Epioscopy on the global market where we see a great interest in our technology. Further, we can happily conclude that there is a significant interest for our company among investors given the solid support in the capital issue from existing shareholders as well as new investors” says Pål Ryfors, acting CEO of Episurf.

Through the Rights Issue, Episurf Medical’s share capital will increase with approximately SEK 4,383,614.75 to SEK 9,172,606.25. The number of A shares will increase by 2,985,597 to 6,386,468 A shares and the number of B shares will increase by 11,614,094 to 24,163,027 B shares. Thus, the total number of shares will increase by 14,599,691 to 30,549,495 shares and the total number of votes will increase by 20,570,885 to 43,322,431 votes.

As confirmation of the allocation of the new A shares and B shares subscribed for without subscription rights, a contract note will be sent to the subscriber or the nominee. Subscribed and allocated new shares shall be paid for in cash on the settlement date in accordance with the instructions on the contract note, around 21 March 2017. Shareholders holding shares through nominees will receive information on allocation in accordance with the routines of respective nominee.

New shares subscribed for with subscription rights are expected to be registered with the Swedish Companies Registration Office on or about 17 March 2017. The BTA will be booked as shares once the entire Rights Issue is registered. New B shares are expected to be admitted to trading on Nasdaq Stockholm during week 13, 2017.

[Aksjesnila]

Dette innebærer da at de som overtegnet får hele overtegningen også?

[Duogdu]

Jeg er glad jeg ikke er en slik kjiping, mine tr er kjøpt og betalt…

[Aksjesnila]

Standupguy you!

Min første emisjonsdeltakelse dette, så jeg prøvde alle variantene, deriblant noen retter til 1,60. Kjempekjøp hehe

[Duogdu]

Oj, da er jo også jeg kjiping! Jeg ga rundt 60 øre😯
Lever greit med det, så for meg rundt 50 øre som minimum, og da var 60 øre ok. Men vi skal vel klare å tjene noen kroner her også

[Duogdu]

Episurf er snart i null hos meg, rt SEK 7,95, jeg har inngang 8,10
Alltid kjekt med blå tall.

[Savepig]

Din gjerrigknark, jeg må vel antagelig være nærmere 12 eller 13.

[Duogdu]

Jeg tenkte å selge på 10-11 kroner

[holmes]

Merkelig at den ikke er fulltegnet men handles på 8.5, ja ja mye gratis arbitrasje som ikke har blitt utnyttet i denne emisjonen

[holmes]

På AAOS nå 15-17 mars

Booth: 2061
We want you to understand how Episurf is improving the lives of individuals with cartilage damage of the knee. Using patient specific MRI data, Episurf is able to create 3D imaging solutions that remove the need for arthroscopies and which then enable the design of a truly personalised resurfacing implant, tailored to every patient’s unique pathology. Visit Episurf to learn how you can offer your patients the latest treatment options for early cartilage lesions

http://s31.a2zinc.net/clients/AAOS/AAOS17/Public/eBooth.aspx?IndexInList=207&FromPage=Exhibitors.aspx&ParentBoothID=&ListByBooth=true&BoothID=141965

[Hakon]

Hadde vært morro med breakthrough i år

[Savepig]

Ser ut som vi bunner ut nå.

[georglu]

Ser BTA-ene begynner å nærme seg 7 kr. Hvor langt ned skal vi før den (sakte, men sikkert?) skal oppover igjen?

[Savepig]

Sjekk volum og meld tilbake, over.

[georglu]

Så i og med det er veldig lavt volum, så er det vanskelig å si om det indikerer noe som helst?

[Savepig]

Basically ja, siden man kan vri kursen flerfoldige prosent for noen tusenlapper.

[georglu]

Ser ut som det er gjort ett salg i dag på 1000 aksjer hvorav de fleste er solgt til 7,10. Ganske stor avstand mellom kjøper og selger nå. Sånn ca. 4 %.

[holmes]

Tror den kan ligge og vake rundt 7.50 en stund, men forhåpentligvis uker og ikke måneder, fremdrift med FDA godkjennelse og evt ny sterk CEO kan hjelpe å få litt fart på kursen.

[holmes]

BTA skal gjøres om til vanlige aksjer denne uken, men har ikke sett noen nærmere dato